| AZN Stock | | | 10,790 236.00 2.24% |
Insider
Chris Sheldon is Head Relations of AstraZeneca PLC
| Address | 1 Francis Crick Avenue, Cambridge, United Kingdom, CB2 0AA |
| Phone | 44 20 3749 5000 |
| Web | https://www.astrazeneca.com |
AstraZeneca PLC Management Efficiency
The company has return on total asset
(ROA) of
0.085 % which means that it generated a profit of $0.085 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
0.1666 %, meaning that it generated $0.1666 on every $100 dollars invested by stockholders. AstraZeneca PLC's management efficiency ratios could be used to measure how well AstraZeneca PLC manages its routine affairs as well as how well it operates its assets and liabilities. At present, AstraZeneca PLC's
Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's
Non Currrent Assets Other is expected to grow to about 5.9
B, whereas
Total Current Assets are forecasted to decline to about 15.3
B.
AstraZeneca PLC (AZN) is traded on London Exchange in UK and employs 89,900 people. AstraZeneca PLC is listed under Pharmaceuticals category by Fama And French industry classification.
Management Performance
AstraZeneca PLC Leadership Team
Elected by the shareholders, the AstraZeneca PLC's board of directors comprises two types of representatives: AstraZeneca PLC inside directors who are chosen from within the company, and outside directors, selected externally and held independent of AstraZeneca. The board's role is to monitor AstraZeneca PLC's management team and ensure that shareholders' interests are well served. AstraZeneca PLC's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, AstraZeneca PLC's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Marc Dunoyer, CEO Officer | |
| Pam Cheng, EVP Board | |
| MBA DVM, CEO Director | |
| Aradhana MD, CFO Director | |
| Katarina Ageborg, Chief Sustainability | |
| Jeffrey Pott, Chief CHRO | |
| Ruud Dobber, Executive Unit | |
| Chris Sheldon, Head Relations | |
| David Fredrickson, Executive Unit | |
| Jeffrey JD, Chief CHRO | |
| Gonzalo Vina, Head Relations | |
| Andrew Barnett, Head Relations | |
| Menelas Pangalos, Executive VicePresident | |
| Leon Wang, Executive President | |
| Susan MD, Executive Development | |
| Iskra Reic, Executive Therapies | |
AstraZeneca Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is AstraZeneca PLC a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Other Information on Investing in AstraZeneca Stock
AstraZeneca PLC financial ratios help investors to determine whether AstraZeneca Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in AstraZeneca with respect to the benefits of owning AstraZeneca PLC security.